Mycophenolate Mofetil in Multiple Sclerosis

Elliot Frohman, Kristen Brannon, Michael K. Racke, Kathleen Hawker

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Objective: To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background: MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5′ -monophosphate dehydrogenase type H, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages. Methods: A retrospective review of experience in treating 79 MS patients with MMF (61 with secondary progressive, 14 with relapsing-remitting, and 4 with primary progressive MS) in the authors' MS center. Results: In most cases, MMF was added as adjunctive therapy in patients already being treated with either interferon-β (n = 44) or glatiramer acetate (n = 20). Fifteen patients not able to use interferon or glatiramer acetate were treated with MMF monotherapy. Seventy percent of the patients continued MMF therapy. Eight patients discontinued therapy because of side effects, 7 patients continued to exhibit evidence of disease progression, 4 were denied insurance coverage, 2 were lost to follow-up, and 1 patient had an elevation of hepatic transaminases that resolved on discontinuation of MMF. One patient discontinued MMF therapy secondary to cytomegalovirus diarrhea. Conclusion: MMF was well tolerated by the majority of patients treated. While these clinical observations were uncontrolled, the clinical course of MS was either unchanged or subjectively improved in many of the treated patients. A randomized controlled trial of MMF in MS, either as monotherapy or in conjunction with interferon or glatiramer acetate, appears warranted.

Original languageEnglish (US)
Pages (from-to)80-83
Number of pages4
JournalClinical Neuropharmacology
Volume27
Issue number2
DOIs
StatePublished - Mar 2004

Fingerprint

Mycophenolic Acid
Multiple Sclerosis
Interferons
IMP Dehydrogenase
Chronic Progressive Multiple Sclerosis
Purine Nucleotides
Therapeutics
Insurance Coverage
Lost to Follow-Up
Guanine
Immunosuppressive Agents
Transaminases
Cytomegalovirus
Disease Progression
Diarrhea
B-Lymphocytes
Randomized Controlled Trials
Macrophages

Keywords

  • Inosine monophosphate dehydrogenase
  • Lymphocytes
  • Multiple sclerosis
  • Mycophenolate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Mycophenolate Mofetil in Multiple Sclerosis. / Frohman, Elliot; Brannon, Kristen; Racke, Michael K.; Hawker, Kathleen.

In: Clinical Neuropharmacology, Vol. 27, No. 2, 03.2004, p. 80-83.

Research output: Contribution to journalArticle

Frohman, Elliot ; Brannon, Kristen ; Racke, Michael K. ; Hawker, Kathleen. / Mycophenolate Mofetil in Multiple Sclerosis. In: Clinical Neuropharmacology. 2004 ; Vol. 27, No. 2. pp. 80-83.
@article{9c4cae4d2ab7497c98bf379e0fb1ee67,
title = "Mycophenolate Mofetil in Multiple Sclerosis",
abstract = "Objective: To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background: MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5′ -monophosphate dehydrogenase type H, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages. Methods: A retrospective review of experience in treating 79 MS patients with MMF (61 with secondary progressive, 14 with relapsing-remitting, and 4 with primary progressive MS) in the authors' MS center. Results: In most cases, MMF was added as adjunctive therapy in patients already being treated with either interferon-β (n = 44) or glatiramer acetate (n = 20). Fifteen patients not able to use interferon or glatiramer acetate were treated with MMF monotherapy. Seventy percent of the patients continued MMF therapy. Eight patients discontinued therapy because of side effects, 7 patients continued to exhibit evidence of disease progression, 4 were denied insurance coverage, 2 were lost to follow-up, and 1 patient had an elevation of hepatic transaminases that resolved on discontinuation of MMF. One patient discontinued MMF therapy secondary to cytomegalovirus diarrhea. Conclusion: MMF was well tolerated by the majority of patients treated. While these clinical observations were uncontrolled, the clinical course of MS was either unchanged or subjectively improved in many of the treated patients. A randomized controlled trial of MMF in MS, either as monotherapy or in conjunction with interferon or glatiramer acetate, appears warranted.",
keywords = "Inosine monophosphate dehydrogenase, Lymphocytes, Multiple sclerosis, Mycophenolate",
author = "Elliot Frohman and Kristen Brannon and Racke, {Michael K.} and Kathleen Hawker",
year = "2004",
month = "3",
doi = "10.1097/00002826-200403000-00006",
language = "English (US)",
volume = "27",
pages = "80--83",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Mycophenolate Mofetil in Multiple Sclerosis

AU - Frohman, Elliot

AU - Brannon, Kristen

AU - Racke, Michael K.

AU - Hawker, Kathleen

PY - 2004/3

Y1 - 2004/3

N2 - Objective: To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background: MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5′ -monophosphate dehydrogenase type H, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages. Methods: A retrospective review of experience in treating 79 MS patients with MMF (61 with secondary progressive, 14 with relapsing-remitting, and 4 with primary progressive MS) in the authors' MS center. Results: In most cases, MMF was added as adjunctive therapy in patients already being treated with either interferon-β (n = 44) or glatiramer acetate (n = 20). Fifteen patients not able to use interferon or glatiramer acetate were treated with MMF monotherapy. Seventy percent of the patients continued MMF therapy. Eight patients discontinued therapy because of side effects, 7 patients continued to exhibit evidence of disease progression, 4 were denied insurance coverage, 2 were lost to follow-up, and 1 patient had an elevation of hepatic transaminases that resolved on discontinuation of MMF. One patient discontinued MMF therapy secondary to cytomegalovirus diarrhea. Conclusion: MMF was well tolerated by the majority of patients treated. While these clinical observations were uncontrolled, the clinical course of MS was either unchanged or subjectively improved in many of the treated patients. A randomized controlled trial of MMF in MS, either as monotherapy or in conjunction with interferon or glatiramer acetate, appears warranted.

AB - Objective: To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background: MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5′ -monophosphate dehydrogenase type H, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages. Methods: A retrospective review of experience in treating 79 MS patients with MMF (61 with secondary progressive, 14 with relapsing-remitting, and 4 with primary progressive MS) in the authors' MS center. Results: In most cases, MMF was added as adjunctive therapy in patients already being treated with either interferon-β (n = 44) or glatiramer acetate (n = 20). Fifteen patients not able to use interferon or glatiramer acetate were treated with MMF monotherapy. Seventy percent of the patients continued MMF therapy. Eight patients discontinued therapy because of side effects, 7 patients continued to exhibit evidence of disease progression, 4 were denied insurance coverage, 2 were lost to follow-up, and 1 patient had an elevation of hepatic transaminases that resolved on discontinuation of MMF. One patient discontinued MMF therapy secondary to cytomegalovirus diarrhea. Conclusion: MMF was well tolerated by the majority of patients treated. While these clinical observations were uncontrolled, the clinical course of MS was either unchanged or subjectively improved in many of the treated patients. A randomized controlled trial of MMF in MS, either as monotherapy or in conjunction with interferon or glatiramer acetate, appears warranted.

KW - Inosine monophosphate dehydrogenase

KW - Lymphocytes

KW - Multiple sclerosis

KW - Mycophenolate

UR - http://www.scopus.com/inward/record.url?scp=2342634617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342634617&partnerID=8YFLogxK

U2 - 10.1097/00002826-200403000-00006

DO - 10.1097/00002826-200403000-00006

M3 - Article

VL - 27

SP - 80

EP - 83

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -